{
  "ticker": "FOLD",
  "company_name": "Amicus Therapeutics",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02363153",
      "title": "Diet and Exercise in Pompe Disease",
      "status": "COMPLETED",
      "phase": "NA",
      "condition": "Pompe Disease, Glycogen Storage Disease Type II, Lysosomal Storage Diseases",
      "start_date": "2017-11-06",
      "completion_date": "2021-05-12",
      "enrollment": 0,
      "sponsor": "University of Florida"
    },
    {
      "nct_id": "NCT03838237",
      "title": "Effect of Migalastat on Cardiac Involvement in Fabry Disease",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Fabry Disease, Heart Diseases",
      "start_date": "2018-01-10",
      "completion_date": "2021-01-22",
      "enrollment": 0,
      "sponsor": "Ospedale San Donato"
    },
    {
      "nct_id": "NCT01218659",
      "title": "Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Fabry Disease",
      "start_date": "2011-09-08",
      "completion_date": "2015-05-28",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT03135197",
      "title": "German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Fabry Disease",
      "start_date": "2017-06-08",
      "completion_date": "2020-06-30",
      "enrollment": 0,
      "sponsor": "University Hospital Muenster"
    },
    {
      "nct_id": "NCT00433147",
      "title": "A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Gaucher Disease, Type 1, Type 1 Gaucher Disease, Gaucher Disease",
      "start_date": "2007-03-23",
      "completion_date": "2008-02-19",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT03158662",
      "title": "Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Epidermolysis Bullosa",
      "start_date": "2017-04-02",
      "completion_date": "2017-06-30",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT00446550",
      "title": "A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1",
      "start_date": "2008-06-11",
      "completion_date": "2009-08-20",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT03729362",
      "title": "A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Pompe Disease (Late-onset)",
      "start_date": "2018-12-04",
      "completion_date": "2021-01-15",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT06904261",
      "title": "A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Fabry Disease",
      "start_date": "2025-12",
      "completion_date": "2028-12",
      "enrollment": 0,
      "sponsor": "Amicus Therapeutics"
    },
    {
      "nct_id": "NCT04129905",
      "title": "Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies",
      "status": "COMPLETED",
      "phase": "NA",
      "condition": "Hypertrophic Cardiomyopathy, Endothelial Dysfunction",
      "start_date": "2019-10-22",
      "completion_date": "2021-12-14",
      "enrollment": 0,
      "sponsor": "University Hospital, Bordeaux"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "NA": 2,
      "": 15,
      "PHASE3": 13,
      "PHASE2": 12,
      "PHASE1": 7,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "COMPLETED": 31,
      "RECRUITING": 4,
      "TERMINATED": 8,
      "AVAILABLE": 3,
      "UNKNOWN": 1,
      "ACTIVE_NOT_RECRUITING": 2,
      "NOT_YET_RECRUITING": 1
    },
    "active_trials": 6,
    "completed_trials": 31,
    "conditions": [
      "Epidermolysis Bullosa",
      "Fabry Disease",
      "Fabry Disease, Heart Diseases",
      "Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1",
      "Gaucher Disease, Type 1, Type 1 Gaucher Disease, Gaucher Disease",
      "Glycogen Storage Disease Type II Infantile Onset",
      "Hypertrophic Cardiomyopathy, Endothelial Dysfunction",
      "Late-onset Pompe Disease",
      "Pompe Disease",
      "Pompe Disease (Late-onset)",
      "Pompe Disease Infantile-Onset",
      "Pompe Disease, Glycogen Storage Disease Type II",
      "Pompe Disease, Glycogen Storage Disease Type II, Lysosomal Storage Diseases",
      "Pompe Disease, Hypersensitivity Reaction",
      "Type 1 Gaucher Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:03:21.767836",
    "search_query": "Amicus Therapeutics",
    "url": "https://clinicaltrials.gov/search?term=Amicus+Therapeutics"
  }
}